TQC2731 + mometasone furoate

TQC2731 + mometasone furoate is a combination therapy under clinical investigation for the treatment of chronic rhinosinusitis with nasal polyps. **TQC2731** is a fully humanized monoclonal antibody targeting thymic stromal lymphopoietin (TSLP), a cytokine involved in type 2 inflammatory pathways. By neutralizing TSLP, TQC2731 blocks signaling that contributes to airway inflammation, making it a potential therapy for diseases such as severe asthma and chronic sinusitis. **Mometasone furoate** is a synthetic glucocorticoid corticosteroid with potent anti-inflammatory properties, typically administered as an intranasal spray to reduce nasal symptoms by suppressing local immune activity. This combination seeks to synergistically reduce inflammation and relapses in chronic rhinosinusitis with nasal polyps through both systemic (TQC2731) and topical (mometasone furoate) mechanisms[1][3][4][5][8].

Brand names

Nasonex

Other names

mometasone furoateTQC2731TQC-2731TQC 2731